Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
Bol Med Hosp Infant Mex. 2020; 77(5):252-261.BM

Abstract

Since the emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China at the end of 2019, when its characteristics were practically unknown, one aspect was evident: its high contagion rate. This high infection rate resulted in the spread of the virus in China, Europe, and, eventually, the rest of the world, including Mexico. At present, around 9 million people are infected, and around 470,000 have died worldwide. In this context, the need to generate protective immunity, and especially the generation of a vaccine that can protect the world population against infection in the shortest possible time, is a challenge that is being addressed in different countries using different strategies in multiple clinical trials. This opinion article will present the evidence of the induction of immune response in some of the viruses of the coronavirus family before COVID-19, such as SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus). The information collected about the induction of an immune response by SARS-CoV-2 will be presented, as well as a description of the vaccine candidates reported to date in the various ongoing clinical trials. Finally, an opinion based on the evidence presented will be issued on the potential success of developing vaccine prototypes.

Links

Publisher Full Text

Authors+Show Affiliations

De León-Rodríguez SG
Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Hernández-Rico B
Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Olmo-Vázquez GD
Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Cruz-Dávalos I
Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Bonifaz LC
Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

MeSH

AnimalsBetacoronavirusCOVID-19COVID-19 VaccinesCoronavirus InfectionsHumansMiddle East Respiratory Syndrome CoronavirusPandemicsPneumonia, ViralSARS VirusSARS-CoV-2Severe Acute Respiratory SyndromeViral Vaccines

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33064679

Citation

De León-Rodríguez, Saraí G., et al. "SARS-CoV-2: Previous Coronaviruses, Immune Response, and Development of Vaccines." Boletin Medico Del Hospital Infantil De Mexico, vol. 77, no. 5, 2020, pp. 252-261.
De León-Rodríguez SG, Hernández-Rico B, Olmo-Vázquez GD, et al. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines. Bol Med Hosp Infant Mex. 2020;77(5):252-261.
De León-Rodríguez, S. G., Hernández-Rico, B., Olmo-Vázquez, G. D., Cruz-Dávalos, I., & Bonifaz, L. C. (2020). SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines. Boletin Medico Del Hospital Infantil De Mexico, 77(5), 252-261. https://doi.org/10.24875/BMHIM.20000191
De León-Rodríguez SG, et al. SARS-CoV-2: Previous Coronaviruses, Immune Response, and Development of Vaccines. Bol Med Hosp Infant Mex. 2020;77(5):252-261. PubMed PMID: 33064679.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines. AU - De León-Rodríguez,Saraí G, AU - Hernández-Rico,Brenda, AU - Olmo-Vázquez,Guadalupe Del, AU - Cruz-Dávalos,Iván, AU - Bonifaz,Laura C, PY - 2020/10/16/entrez PY - 2020/10/17/pubmed PY - 2020/10/28/medline KW - Ad5-nCoV vaccine KW - Bacillus Calmette-Guerin KW - Bacilo de Calmette-Guérin KW - COVID-19 vaccine KW - Coronavirus de Wuhan KW - SARS-CoV-2 vaccine KW - Vacuna Ad5-nCoV KW - Vacuna COVID-19 KW - Vacuna SARS-CoV-2 KW - Vacuna mRNA-1273 KW - Wuhan coronavirus KW - mRNA 1273 vaccine SP - 252 EP - 261 JF - Boletin medico del Hospital Infantil de Mexico JO - Bol Med Hosp Infant Mex VL - 77 IS - 5 N2 - Since the emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China at the end of 2019, when its characteristics were practically unknown, one aspect was evident: its high contagion rate. This high infection rate resulted in the spread of the virus in China, Europe, and, eventually, the rest of the world, including Mexico. At present, around 9 million people are infected, and around 470,000 have died worldwide. In this context, the need to generate protective immunity, and especially the generation of a vaccine that can protect the world population against infection in the shortest possible time, is a challenge that is being addressed in different countries using different strategies in multiple clinical trials. This opinion article will present the evidence of the induction of immune response in some of the viruses of the coronavirus family before COVID-19, such as SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus). The information collected about the induction of an immune response by SARS-CoV-2 will be presented, as well as a description of the vaccine candidates reported to date in the various ongoing clinical trials. Finally, an opinion based on the evidence presented will be issued on the potential success of developing vaccine prototypes. SN - 1665-1146 UR - https://www.unboundmedicine.com/medline/citation/33064679/SARS_CoV_2:_previous_coronaviruses_immune_response_and_development_of_vaccines_ L2 - http://www.bmhim.com/frame_esp.php?id=176 DB - PRIME DP - Unbound Medicine ER -